Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148947 · ClinicalTrials.gov registry record · Phase 2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
A Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT07148947: Recruiting Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm, sponsored by University of Washington.
NCT07148947 is a Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm that is actively recruiting participants, run by University of Washington. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148947, a Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine and decitabine are in a class of medications called hypomethylation agents. They work by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Adding pacritinib to standard of care azacitidine or decitabine may increase the number of patients able to proceed to hematopoietic stem cell transplantation for patients with accelerated and blast phase myeloproliferative neoplasms.
Primary Outcome
Will be estimated and reported with a 95% confidence interval using methodology to account for the two-stage design.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- OTHER Survey Administration
- DRUG Decitabine and Cedazuridine
- DRUG Pacritinib
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT07148947 shows while recruiting
NCT07148947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Accelerated Phase Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Azacitidine is the first listed.
NCT07148947 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07148947 about?
NCT07148947 is a clinical study titled "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms". This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritinib may stop the grow...
What is the current status of trial NCT07148947?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2026-03-02. Estimated completion is 2028-12-31.
What conditions does trial NCT07148947 study?
This clinical trial studies the following conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT07148947?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Survey Administration (OTHER), Decitabine and Cedazuridine (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT07148947?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148947 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Accelerated Phase Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07148947's enrollment target sits among peer trials
27 1697th of 2000 higher than 294 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI